A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH) (NATIVE)

10th July 2018 - ongoing

Status: Active

Specialism: Liver.

Team: Dr Stephen Ryder.

People

Photo	Name	Bio
	Dr Stephen Ryder